OC
INDP icon

Oppenheimer & Co’s Indaptus Therapeutics INDP Stock Holding History

Oppenheimer & Co’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7
Closed -$12K – 1291
2019
Q3 		$12K Buy
+7
New +$20.8K ﹤0.01% 1248

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Oppenheimer & Co's INDP Position: Q4 2019 in Review

Oppenheimer & Co sold out of Indaptus Therapeutics (INDP) in Q4 2019, closing a stake of 7 shares — an estimated $12K sold.

Oppenheimer & Co first reported a position in INDP in Q3 2019 and held it in 1 quarter. The position peaked at $12K in Q3 2019. 25 funds tracked by Wall St. Rank hold INDP as of Q4 2019.

  • Oppenheimer & Co reported no remaining Indaptus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 7 Indaptus Therapeutics shares in Q4 2019, an estimated $12K.
  • Oppenheimer & Co first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 1 quarter.
  • Oppenheimer & Co's Indaptus Therapeutics position peaked at $12K in Q3 2019.
  • 25 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q4 2019.

Based on Oppenheimer & Co's 13F filing for Q4 2019, filed 7 Feb 2020.